• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
GYN
CMECNE

ACOG and AUGS Guidance: Asymptomatic Microscopic Hematuria in Women

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Incorporate appropriate urine sample collection into care
2. List appropriate criteria where no further evaluation for hematuria is required because of a low risk of malignancy

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Dec 31 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

SUMMARY:

ACOG and AUGS released joint guidance on the screening and management of asymptomatic microscopic hematuria in women.  The data suggests that women at low risk for urinary tract malignancy (bladder, ureter and kidney) do not necessarily need follow up for asymptomatic microscopic hematuria.

Sample Collection

  • Positive dipstick does not define asymptomatic microscopic hematuria but should generate a urinalysis and microscopic examination of urinary sediment
  • A voided midstream sample is the recommended collection method for diagnosis
  • Women have sex-specific risks for contamination (false positives) due to the following conditions
    • Menstruation
    • Urogenital atrophy
    • Pelvic organ prolapse

ACOG & AUGS 2017

  • No further evaluation required for low risk women that meet the following criteria (risk of malignancy ≤ 0.5%)
    • Asymptomatic
    • Never-smoking
    • Age 35 to 50
    • ≤ 25 red blood cells per high-power field
  • As part of the Choosing Wisely Campaign (2020), AUGS continues to support limiting interventions and states

Asymptomatic hematuria in women is common but less likely to be associated with a urinary tract malignancy compared to men

Data support changing the evaluation requirements for microscopic hematuria in this low-risk group of women

Organizations which do not risk-stratify based on gender may continue to recommend more aggressive diagnostic evaluation in low-risk women

USPSTF  2011

  • No recommendation because current evidence is insufficient to assess the balance of benefits and harms of screening for bladder cancer in asymptomatic adults

AUA & SUFU

  • AUA and SUFU define microhematuria as follows
    • ≥3 red blood cells per high powered field
    • Properly collected urinary specimen
  • Positive dipstick does not define microhematuria but should generate a urinalysis and microscopic examination of urinary sediment
  • Urine biomarkers (e.g., NMP22) are not recommended for use in routine evaluation
  • Guidelines use a risk stratification algorithm to determine follow-up (low, intermediate or high risk)
    • Low risk: Women age <50 | Men age <40 yrs | Never smoker or <10 pack-years | 3 to 10 RBC/HPF on one UA | No additional risk factors for urothelial cancer1 No prior episodes of microhematuria
    • In the case of low risk microhematuria, the guideline states that 6 month follow up should be discussed with the patient in the context of shared decision making

…clinicians should discuss cystoscopy and imaging with renal ultrasound as options for evaluation, but should also review the option to repeat UA, with a plan to escalate to cystoscopy and imaging if the MH is found to persist

Key Points:

  • Hematuria is associated with urinary tract malignancy and early detection of tumors with malignant potential could have an important effect on the mortality rate of bladder cancer (USPSTF)
  • Risk factors for bladder cancer include:
    • Smoking
    • Occupational exposure to carcinogens (e.g., rubber, chemical, and leather industries)
    • Male sex
    • Older age
    • White race
    • Infections caused by certain bladder parasites (e.g., Schistosoma haematobium)
    • Family or personal history of bladder cancer
  • Asymptomatic microscopic hematuria is common in women (ranges from 2.4% to 31.1%)
    • Less likely to be associated with urinary tract malignancy in women than men
    • ACOG and AUGS recommend that going forward, professional organizations produce sex-specific recommendations
  • Harms associated with false positive screening results include
    • Anxiety
    • Unnecessary evaluations (e.g., CT radiation exposure) and treatments
    • Diagnostic-related from cystoscopy and biopsy
    • Overdiagnosis and overtreatment

Learn More – Primary Sources:

ACOG / AUGS Committee Opinion 703: Asymptomatic Microscopic Hematuria in Women

AUGS: Choosing Wisely Campaign

Microhematuria: AUA/SUFU Guideline

USPSTF: Bladder Cancer in Adults: Screening

Take a post-test and get CME credits

TAKE THE POST TEST

Want to hear about the latest clinical summaries via ObG Insider?

Get Your Free e-Newsletter »

image_pdfFavoriteLoadingFavorite

< Previous
All GYN Posts
Next >

Related ObG Topics:

Practical gynecology info for your women's healthcare practice
Primary Care Screening: USPSTF Recommendations for Your Patient
Ovarian or Endometrial Cancer? Consider Lynch Syndrome
Urinary Incontinence – How to Make the Diagnosis in Your Office and When to Refer

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site